VC firms
OS Fund invests in entrepreneurs using applied intelligence to commercialize breakthrough discoveries in genomics, synthetic biology, diagnostics, new materials, and data and energy. We seek out platform enabling technologies that accelerate discovery and commercialization. We never invest in a single molecule, model or algorithm. We do hard science investing with technology level risk.
We work with our portfolio companies to develop foundational IP that solves real-world challenges and paves a path for commercialization. We’ve thoughtfully constructed a cross-disciplinary group of companies that are each uniquely contributing to the robust ecosystem they all need to thrive.
We work with our portfolio companies to develop foundational IP that solves real-world challenges and paves a path for commercialization. We’ve thoughtfully constructed a cross-disciplinary group of companies that are each uniquely contributing to the robust ecosystem they all need to thrive.
Overview
Location
United States, Illinois, Chicago
Employees
1-10
Founded date
2014
Investment Type
Venture Capital
Investment Stage
Series A
Portfolio 35
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| May 6, 2021 | Aria Pharmaceuticals | ariapharmaceuticals.com | United States, California, Palo Alto | |
| Jul 17, 2020 | Viv | viv.ai | $12.5M | United States, California, San Jose |
| Jul 17, 2020 | Health Data Link | healthdata.link | ||
| Apr 28, 2020 | Kenota Health | kenota.com | $9M | Canada, Ontario, Kitchener |
| Mar 19, 2018 | twoXAR | twoxar.com | $13.4M | |
| Nov 29, 2017 | Arzeda | arzeda.com | $98.2M | |
| Dec 13, 2016 | Lygos | lygos.com | $50.5M | United States, California, Berkeley |
| Exvivo | exvivo.com | Canada, Ontario, Waterloo | ||
| Nanoly | nanoly.info |
Show more
News 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 8, 2021 | Q4 2020 Portfolio Company Updates: The Biotech Revolution, COVID-19 Vaccines and At-Home Testing, Partnerships and Funding News | The seismic shifts of 2020 have sparked an acceleration of innovations which have armed humanity with awareness and ability to create powerful, longstanding positive impact via next generation... |
| Oct 22, 2020 | Q3 2020 Portfolio Company Updates: Adaptability and Future Literacy, COVID-19 Testing, Partnership and Funding News | There is no doubt that the complex impact of the coronavirus pandemic has challenged us all to reflect on previous strategies, both personally and professionally, and adapt to the rapidly evolving... |
| Scaling AI-Driven Drug Discovery: twoXAR Signs Four Partnerships in a Year and Celebrates Five-year Anniversary | Last year we announced our investment in twoXAR, a company building a next generation drug discovery platform. As twoXAR’s five-year anniversary comes to pass, they have managed to vastly exceed... | |
| Q2 2020 Portfolio Company Updates: The Fight Against COVID-19, Sustainability Successes, AI for Drug Discovery Victories | The second quarter was an unprecedented time in our history; and while much of the world remains in various states of shutdown, our areas of focus at OS Fund have taken center stage. Companies, not... | |
| OS Fund — Building A Global Biological Immune System | Increasing the probability that the human race will thrive. tl:dr After selling my company Braintree (Venmo) to eBay in 2013, I started a venture fund, OS Fund, personally investing $100M. My... | |
| The most incredible technology you’ve never seen | There’s money to be made and lives to be saved with the tiny stuff that’s all around us. Saving the world (or some subset of people in it) is in vogue among the world’s wealthiest. Jeff Bezos... | |
| Re-writing Nature’s Recipe Book: How Ginkgo Bioworks is Poised to Upset Almost Every Industry You Can Think Of | Ginkgo Bioworks, based in Boston, has been in the headlines lately: Ginkgo will “bring biodesign to the masses”. (Fast Company.) Ginkgo will “convince you to love GMOs”. (The Atlantic.)... | |
| Synthego: The One Stop Shop for Revolutionary Genetic Research | This article is part of a series about how OS Fund (OSF) companies are radically redefining our future by rewriting the operating systems of life. Or as we prefer to think about it: Step 1: Put... | |
| A Lesson From SARS-CoV-2: We Need to Build A Real-Time Global Biological Immune System | A coronavirus has ravaged our planet. Humanity brought to its knees by 29,829 nucleotides of “bad news wrapped in a protein.” In 2014, Jeff Klunzinger and I designed OS Fund to build... |
Mentions in press and media 28
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 24, 2019 | A-Alpha Bio raises $2.8M for genetically engineered drug discovery platform | The A-Alpha Bio team includes scientist Emily Engelhart, principal scientist David Colby, co-founder and CEO David Younger, co-founder and chief technology officer Randolph Lopez and engineering associate Charles Lin. (A-Alpha Bio Photo) A ... |
| Jan 29, 2019 | Houston needs 4 things to emerge as a startup hub, according to this entrepreneur | I often think about why Houston's entrepreneurship ecosystem hasn't taken off as much as it should, given the talent pool and the industrial gravity that's concentrated here. I joined Station Houston as one of the very early members in Janu... |
| Sep 21, 2018 | Biotech Startup uBiome Raises $83M to Expand World’s Largest Human Microbiome Database | uBiome, a microbial genetics company leveraging artificial intelligence to develop wellness products, clinical tests, and therapeutics based on the microbiome, today announced it has raised $83 million in Series C funding. The round was led... |
| Aug 7, 2018 | OS Fund to Raise $250M to Back Startups Solving Global Problems | OS Fund, a Venice, CA-based venture capital firm that invests in entrepreneurs and companies that develop breakthrough discoveries in science to address the most pressing global problems, is raising $250m for OS Fund II. This raise follows ... |
| Mar 19, 2018 | Bioinformatics startup twoXAR bags $10M in Series A | JP Lee, managing director of SoftBank Ventures, will join Andreessen Horowitz general partner Vijay Pande on the twoXAR board of directors. Palo Alto, California-based twoXAR reached this next stage of growth thanks to $3.4 million in seed ... |
| Mar 19, 2018 | TwoXar raises $10 million from SoftBank, Andreessen Horowitz, and OS Fund to grow its AI drug discovery platform | TwoXar, a biopharmaceutical startup that uses artificial intelligence (AI) to identify and develop new medicines, has raised $10 million in a series A round of funding led by SoftBank’s early-stage venture capital firm, SoftBank Ventures, w... |
| Mar 19, 2018 | TwoXar raises $10 million from SoftBank, Andreessen Horowitz, and OS Fund to grow its AI drug discovery platform | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more. TwoXar, a biopharmaceutical startup that uses artificial intelligence (AI) to identify and develop new medicines, has raised $10 millio... |
| Nov 30, 2017 | UPDATE: Arzeda Closes Series A on $15.2m for Plant-Based Computational Protein Production, Led by OS Fund | *First published July 27, 2017. Updated November 30 to reflect final close on $15.2 million Seattle-based Arzeda has raised a $15.2 million Series A round to expand the capacity of its synthetic protein and enzyme development operation. The... |
| Oct 30, 2017 | Five Startups Set to Disrupt Your Kid’s Halloween Candy | It’s a scary fact for any parent, particularly at bedtime tomorrow: children eat an average of three cups of sugar on Halloween, according to industry estimates. Consensus on nutrition is a rare thing, but the goal of reducing sugar intake ... |
Show more
Reviews 0
FAQ about OS Fund
When was OS Fund founded?
OS Fund was founded in 2014.
How many startups has OS Fund invested in?
OS Fund has 35 portfolio companies on Parsers VC, among them Aria Pharmaceuticals, Viv and Health Data Link.
What is the latest news about OS Fund?
Parsers VC has 10 news items about OS Fund, among them “Q4 2020 Portfolio Company Updates: The Biotech Revolution, COVID-19 Vaccines and At-Home Testing, Partnerships and Funding News” (Jan 8, 2021) and “Q3 2020 Portfolio Company Updates: Adaptability and Future Literacy, COVID-19 Testing, Partnership and Funding News” (Oct 22, 2020).
What has the press written about OS Fund?
Parsers VC has collected 28 articles mentioning OS Fund, among them “A-Alpha Bio raises $2.8M for genetically engineered drug discovery platform” (Sep 24, 2019) and “Houston needs 4 things to emerge as a startup hub, according to this entrepreneur” (Jan 29, 2019).
Is OS Fund still active?
Yes, OS Fund is active; its latest activity on Parsers VC dates from Nov 21, 2021.